RZLT
NASDAQ · Biotechnology
Rezolute Inc
$5.02
+0.23 (+4.80%)
Open$4.84
Previous Close$4.79
Day High$5.16
Day Low$4.84
52W High$11.46
52W Low$1.07
Volume—
Avg Volume2.08M
Market Cap483.39M
P/E Ratio—
EPS$-0.81
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+245.6% upside
Current
$5.02
$5.02
Target
$17.35
$17.35
$11.58
$17.35 avg
$20.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.23M | 44.79M | 46.31M |
| Net Income | 4.09M | 3.84M | 4.53M |
| Profit Margin | 9.0% | 8.6% | 9.8% |
| EBITDA | 6.09M | 5.25M | 5.80M |
| Free Cash Flow | 2.47M | 3.54M | 3.43M |
| Rev Growth | +6.6% | +21.1% | +6.0% |
| Debt/Equity | 0.15 | 0.18 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.93 | +0.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $352.99 | +1.72% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.88 | +0.66% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $478.81 | +2.22% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $626.31 | +1.34% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $300.33 | +4.22% | 64.3 | 37.13B |